Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Kay

Showing results (171-180 of 325) with videos related to

Pageof 33
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 23, 2012
A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 regionJames R Cerhan, Zachary S Fredericksen, Anne J Novak, et al.
Plos One|December 31, 2013
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cellsStefania Fiorcari, Wells S Brown, Bradley W McIntyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemiaTait D Shanafelt, Neil E Kay, Kari G Rabe, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Blood Neoplasia|June 2, 2025
Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemiaOlivia M Depies, Qianqian Guo, Yuan Gao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2008
Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphomaJames R Cerhan, Wen Liu-Mares, Zachary S Fredericksen, et al.
The New England Journal of Medicine|August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaLaura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Blood|September 19, 2009
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceAntonina V Kurtova, Kumudha Balakrishnan, Rong Chen, et al.
Blood|May 3, 2002
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patientsRafael Fonseca, Emily A Blood, Martin M Oken, et al.
Pageof 33

Showing results (171-180 of 325) with videos related to

Sort By:
Pageof 33
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 23, 2012
A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 regionJames R Cerhan, Zachary S Fredericksen, Anne J Novak, et al.
Plos One|December 31, 2013
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cellsStefania Fiorcari, Wells S Brown, Bradley W McIntyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemiaTait D Shanafelt, Neil E Kay, Kari G Rabe, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Blood Neoplasia|June 2, 2025
Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemiaOlivia M Depies, Qianqian Guo, Yuan Gao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2008
Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphomaJames R Cerhan, Wen Liu-Mares, Zachary S Fredericksen, et al.
The New England Journal of Medicine|August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaLaura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Blood|September 19, 2009
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceAntonina V Kurtova, Kumudha Balakrishnan, Rong Chen, et al.
Blood|May 3, 2002
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patientsRafael Fonseca, Emily A Blood, Martin M Oken, et al.
Pageof 33